Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $877K fell 54.4% year over year, behind the -25.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 53.4% from the prior quarter. Over 3 fiscal years it compounded at -14.4% a year.

Context

  • Depreciation & amortization amounted to 19.2% of revenue in FY2025, up 3.0 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -54.4% toward the trailing-twelve-month pace of -25.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$877K-53.4% QoQ
Last fiscal yearDec 2025
$7.6M-18.8% YoY
LTMMar 2026
$6.56M-25.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.4%——
1 year-18.8%——
3-year CAGR-14.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
7.6M USD
Year-over-year change
-18.8%
4-year CAGR
-19.0%

Depreciation & Amortization vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.2% is the 9th highest of 11, against a peer median of +7.9%.
  • Depreciation & amortization amounts to 19.0% of revenue for SGMO, versus a peer median of 25.6%.
SGMO Competitors
Depreciation & Amortization for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$23.01M USD-1.6%+6.0%79.6%
CDXSCodexis, Inc.LTM Mar 2026$8.57M USD+6.1%-1.0%11.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$6.56M USD-25.2%-14.4%19.0%
IPHAInnate Pharma S.A.FY2025€5.09M EUR+155.3%-51.8%182.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$3.3M USD-47.7%+5.3%9.5%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF+9.7%-3.5%—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.34M USD+35.9%-25.1%119.9%
IVVDInvivyd, Inc.LTM Mar 2026$1.88M USD-43.4%+65.8%3.4%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$1.61M USD+16.3%+19.7%54.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$810K USD-21.4%+18.0%25.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$143K USD+37.5%+8.6%8.0%
Peer median (excluding SGMO) —+7.9%+5.7%25.6%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.